Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.
Covered in this story
What has happened since
- Associated Bancorp is down 1.0% since this was published, 45 days ago.
- Parker Hannifin is down 7.9% since this was published, 45 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ASB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Associated Bancorp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.